Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to Design's conference call. At this time, all participants are in a listen-only mode. There will be a question and answer session after the prepared remarks. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Dr. Shawn Jeffries, Chief Operating Officer of Design Therapeutics. You may begin. Welcome, and thank you for joining us today. Earlier, we issued a press release outlining our fourth quarter and full year 2023 financial results and updates across our portfolio of GeneTAC small molecule genomic medicines. The slides that we'll be using today during today's call will be available along with the recording of this call in the investor section of our website at designTX.com. I'm Sean Jeffries, Chief Operating Officer of Design, and I'm joined today on a call by our Chairman and CEO, Dr. Prateek Shah. During this call, we will use forward-looking statements related to our current expectations and plans, including our program development plans, which are subject to risk and uncertainties. Actual results may differ materially due to various important factors, including those described in the risk factors section of our most recently filed Form 10-K. These statements represent our views as of this call and should not be relied upon as representing our views as of any date in the future. We take no obligation to publicly update any forward-looking statements. With that, I'd like to turn the call over to Dr. Shah. Thank you, Dr. Jeffries, and good afternoon, everyone. I'm excited to present Design Therapeutics' first significant update for 2024. What makes this company unique and compelling is that we have discovered a new class of small molecules that are designed to dial up ...